Grifols, S.A. (NASDAQ:GRFS) is a company that unfortunately has not been performing as I expected it to. My position is in the green, but this has more to do with FX and me adding shares below my ...

Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from ...

Grifols (GRFS) has established a partnership with the Biomedical Advanced Research and Development Authority to test investigational ocular ...

Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure to sulfur mustard, a chemical warfare ...

Grifols fully acquired GigaGen in 2021 for $80 million, after first investing $50 million in the biotech in 2017 for a deal to develop polyclonal antibodies. GigaGen first snagged the spotlight ...

Episode three of The Leaders’ Room’s season two features Grifols Ireland lead, Shane O’Brien. This series is created in partnership with IDA Ireland.

Spanish drugmaker Grifols SA is being sanctioned by the country’s markets regulator for “misleading reporting,” a blow for the pharmaceutical company as it deals with a takeover approach ...

LONDON, Sept 30 (Reuters) - Canadian fund Brookfield (BN.TO), opens new tab reaffirmed its interest in a potential takeover of Spanish drugmaker Grifols (GRLS.MC), opens new tab and requested more ...

Grifols SA has entered into a partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to ...

El Economista Grupo Editorial, S.a. De C.v. Sept 30 (Reuters) - Spanish drugmaker Grifols (GRLS.MC), opens new tab plans to invest 360 million euros ($401.98 million) to build a new industrial ...

BARCELONA, Spain, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived ...